Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).

被引：0
|
作者：
Cremolini, Chiara
Loupakis, Fotios
Yang, Dongyun
Salvatore, Lisa
Zhang, Wu
Wakatsuki, Takeru
Schirripa, Marta
Lonardi, Sara
Antoniotti, Carlotta
Aprile, Giuseppe
Masi, Gianluca
Graziano, Francesco
Ruzzo, Annamaria
Lucchesi, Sara
Ronzoni, Monica
Maus, Martin Karl Herbert
Bocci, Guido
Tonini, Giuseppe
Falcone, Alfredo
Lenz, Heinz-Josef
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] IRCCS, Ist Oncolog Veneto, Padua, Italy
[4] Azienda Osped Univ Udine, Udine, Italy
[5] UOC Oncol AO, Pesaro, Italy
[6] Univ Urbino, Sect Biochem & Mol Biol, Dept Biomol Sci, I-61029 Urbino, Italy
[7] Osped Pontedera, UO Oncol Med, Pontedera, Italy
[8] Ist Sci San Raffaele, Dipartimento Oncol, Milan, Italy
[9] Response Genet Inc, Los Angeles, CA USA
[10] Univ Pisa, Div Chemotherapy & Pharmacol, Dept Internal Med, Pisa, Italy
[11] Univ Campus Biomed, Rome, Italy
[12] Univ Pisa, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    Annamaria Ruzzo
    Lisa Salvatore
    Chiara Cremolini
    Gianluca Masi
    Paolo Frumento
    Marta Schirripa
    Vincenzo Catalano
    Nadia Galluccio
    Emanuele Canestrari
    Bruno Vincenzi
    Daniele Santini
    Katia Bencardino
    Vincenzo Ricci
    Mariangela Manzoni
    Marco Danova
    Giuseppe Tonini
    Mauro Magnani
    Alfredo Falcone
    Francesco Graziano
    [J]. BMC Cancer, 11
  • [32] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Loupakis, Fotios
    Ruzzo, Annamaria
    Salvatore, Lisa
    Cremolini, Chiara
    Masi, Gianluca
    Frumento, Paolo
    Schirripa, Marta
    Catalano, Vincenzo
    Galluccio, Nadia
    Canestrari, Emanuele
    Vincenzi, Bruno
    Santini, Daniele
    Bencardino, Katia
    Ricci, Vincenzo
    Manzoni, Mariangela
    Danova, Marco
    Tonini, Giuseppe
    Magnani, Mauro
    Falcone, Alfredo
    Graziano, Francesco
    [J]. BMC CANCER, 2011, 11
  • [33] Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI plus bevacizumab
    Budai, Barna
    Komlosi, Viktor
    Adleff, Vilmos
    Pap, Eva
    Reti, Andrea
    Nagy, Tuende
    Kralovanszky, Judit
    Lang, Istvan
    Hitre, Erika
    [J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (01): : 69 - 72
  • [34] ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Liver and/or lung metastasectomy after cetuximab or bevacizumab plus FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
    Kim, Sang-A
    Kim, Ji-Won
    Suh, Koung Jin
    Kim, Jin Won
    Oh, Heung-Kwon
    Cho, Jai Young
    Kim, Duck-Woo
    Lee, Keun-Wook
    Cho, Sukki
    Kim, Jee Hyun
    Kim, Kwhanmien
    Kang, Sung-Bum
    Jheon, Sanghoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] CCL2 polymorphism as a predictive marker for bevacizumab (Bev) hi combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts)
    Siamak, Saadat
    Sunakawa, Yu
    Loupakis, Fotios
    Yang, Dongyun
    Zhang, Wu
    Ning, Yan
    Stintzing, Sebastian
    Stremitzer, Stefan
    Seblo, Ana
    Yamauchi, Shinichi
    Matsusaka, Satoshi
    El-Khoueiry, Rita Elie
    Antoniotti, Carlotta
    Rossini, Daniele
    Cremolini, Chiara
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] Xeliri Plus Bevacizumab Compared with Folfiri Plus Bevacizumab as First-Line Setting in Patients with Metastatic Colorectal Cancer: Experiences at Two-Institutions
    Uygun, Kazim
    Bilici, Ahmet
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (04) : 2283 - 2288
  • [39] FOLFIRI VS FOLFIRI plus BEVACIZUMAB IN FIRST-LINE THERAPY OF METASTATIC COLORECTAL CANCER: RETROSPECTIVE ANALYSIS OF 81 PATIENTS IN OUR INSTITUTION
    Rakusic, Z.
    Jajac, L.
    Juretic, A.
    Bisof, V.
    Misir-Krpan, A.
    Santek, F.
    Basic-Koretic, M.
    Plestina, S.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 217 - 217
  • [40] AN EZH2 POLYMORPHISM PREDICTS PROGRESSION-FREE SURVIVAL (PFS) IN METASTATIC COLORECTAL CANCER (CRC) PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV)
    Crea, F.
    Fornaro, L.
    Paolicchi, E.
    Masi, G.
    Loupakis, F.
    Salvatore, L.
    Farrar, W. L.
    Falcone, A.
    Danesi, R.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 65 - 65
12345